Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Rimonabant: more than an anti-obesity drug?

Costa B.

Br J Pharmacol. 2007 Mar;150(5):535-7. Epub 2007 Jan 22.

2.

[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].

Ducobu J, Sternon J.

J Pharm Belg. 2005;60(3):89-91. Review. French.

PMID:
16252510
3.

Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?

Doggrell SA.

Expert Opin Pharmacother. 2005 Oct;6(12):2141-4. Review. No abstract available.

PMID:
16197364
4.

The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.

Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB.

J Clin Pharm Ther. 2007 Jun;32(3):209-31. Review.

PMID:
17489873
5.

Pleiotropic effects of rimonabant: clinical implications.

Després JP.

Curr Pharm Des. 2009;15(5):553-70. Review.

PMID:
19199981
6.

Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.

Patel PN, Pathak R.

Am J Health Syst Pharm. 2007 Mar 1;64(5):481-9. Review.

PMID:
17322160
7.

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

Scheen AJ.

J Neuroendocrinol. 2008 May;20 Suppl 1:139-46. doi: 10.1111/j.1365-2826.2008.01681.x. Review.

8.

Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.

Bifulco M, Grimaldi C, Gazzerro P, Pisanti S, Santoro A.

Mol Pharmacol. 2007 Jun;71(6):1445-56. Epub 2007 Feb 27. Review.

9.

Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.

Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV.

Pharmacol Rep. 2009 Mar-Apr;61(2):217-24. Review.

10.

[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].

Boekholdt SM, Jukema JW, Peters RJ.

Ned Tijdschr Geneeskd. 2007 Nov 24;151(47):2615-9. Review. Dutch.

PMID:
18161262
11.
12.

CB1 antagonists for obesity--what lessons have we learned from rimonabant?

Di Marzo V, Després JP.

Nat Rev Endocrinol. 2009 Nov;5(11):633-8. doi: 10.1038/nrendo.2009.197. Review.

PMID:
19844251
13.

Endocannabinoid control of food intake and energy balance.

Di Marzo V, Matias I.

Nat Neurosci. 2005 May;8(5):585-9. Review.

PMID:
15856067
14.

The endocannabinoid system as a novel approach for managing obesity.

Lillo JL.

J Am Osteopath Assoc. 2007 Apr;107(4 Suppl 2):S12-20. Review.

PMID:
17784530
15.

CB(1) receptor antagonism: biological basis for metabolic effects.

Di Marzo V.

Drug Discov Today. 2008 Dec;13(23-24):1026-41. doi: 10.1016/j.drudis.2008.09.001. Epub 2008 Oct 15. Review.

PMID:
18824122
16.

Rimonabant--a selective CB1 antagonist.

Boyd ST, Fremming BA.

Ann Pharmacother. 2005 Apr;39(4):684-90. Epub 2005 Mar 8. Review.

PMID:
15755787
17.
18.

[Endocannabinoid and endocannabinoid receptor antagonists].

Heinzl S.

Med Monatsschr Pharm. 2005 Feb;28(2):40-3. Review. German. No abstract available.

PMID:
15727333
19.

Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.

Pavón FJ, Serrano A, Pérez-Valero V, Jagerovic N, Hernández-Folgado L, Bermúdez-Silva FJ, Macías M, Goya P, de Fonseca FR.

J Neuroendocrinol. 2008 May;20 Suppl 1:116-23. doi: 10.1111/j.1365-2826.2008.01693.x. Review.

PMID:
18426510
20.

Contribution of CB1 blockade to the management of high-risk abdominal obesity.

Després JP, Lemieux I, Alméras N.

Int J Obes (Lond). 2006 Apr;30 Suppl 1:S44-52. Review.

PMID:
16570106

Supplemental Content

Support Center